Compugen (NASDAQ:CGEN) Cut to “Hold” at lowered shares of Compugen (NASDAQ:CGENFree Report) from a buy rating to a hold rating in a research report released on Monday morning.

Compugen Stock Performance

CGEN opened at $2.21 on Monday. The business’s 50-day simple moving average is $2.30 and its 200-day simple moving average is $1.83. The company has a market cap of $191.43 million, a P/E ratio of -10.05 and a beta of 2.72. Compugen has a one year low of $0.53 and a one year high of $3.03.

Compugen (NASDAQ:CGENGet Free Report) last released its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The firm had revenue of $33.46 million for the quarter, compared to analysts’ expectations of $60.00 million. As a group, analysts predict that Compugen will post 0.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CGEN. Kingsview Wealth Management LLC purchased a new position in Compugen during the 3rd quarter worth approximately $78,000. Tocqueville Asset Management L.P. purchased a new position in shares of Compugen in the 3rd quarter valued at approximately $71,000. Silverarc Capital Management LLC grew its stake in shares of Compugen by 6.1% in the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Heron Bay Capital Management purchased a new position in shares of Compugen in the 1st quarter valued at approximately $32,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

(Get Free Report)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Read More

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with's FREE daily email newsletter.